{
    "clinical_study": {
        "@rank": "88964", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Days 1, 9 and 13: Healthy Volunteers will take IDX719 in the mornings under fed or fasted conditions.\nDays 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Days 1, 9 and 13: Healthy Volunteers will take IDX719 in the mornings under fasted conditions.\nDays 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the potential for an effect of Ritonavir (Norvir\u00ae) or\n      omeprazole (Prilosec\u00ae) on the pharmacokinetics of IDX719 and to assess the safety and\n      tolerability of the study drugs when administered alone and in combination in healthy\n      subjects."
        }, 
        "brief_title": "To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read and signed the written informed consent form (ICF) after the nature of the study\n             has been fully explained.\n\n          -  All subjects of childbearing potential must have agreed to use a double method of\n             birth control (one of which must be a barrier) from Screening through at least 90\n             days after the last dose of the study drug.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813552", 
            "org_study_id": "IDX-06A-006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "description": "IDX719 150 mg tablets (50mg x 3), single dose", 
                "intervention_name": "IDX719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "40 mg delayed-release capsules, once daily", 
                "intervention_name": "Omeprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group A", 
                "description": "100 mg tablets, once daily", 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Omeprazole", 
                "Ritonavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV", 
            "Hepatitis C", 
            "antiviral drugs", 
            "liver"
        ], 
        "lastchanged_date": "March 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lincoln", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "80837"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I, Randomized, Open-label Study to Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic parameters of plasma drug exposure (AUC0-t, AUCss, Cmax and Ctrough) of IDX719 and ritonavir (RTV) under fasted and fed conditions\nPharmacokinetic parameters  of plasma drug exposure (AUC0-t, AUCss, Cmax and Ctrough) of IDX719 and omeprazole (OMZ) under fasted conditions", 
            "measure": "Pharmacokinetic parameters", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 17 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "- Safety and tolerability of IDX719 and RTV or OMZ, alone and in combination, using key safety parameters (adverse events, physical examinations, vital signs, ECGs and standard laboratory safety tests).", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 17 days"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}